Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.50 |
| ▸ | CA1 | P00915 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979185 | 0.94 | CA2 (0.52) | CA2CA1CA12CA9CA14 | |
| SCHEMBL20032423 | 0.90 | CA2 (0.55) | CA2CA1CA12CA9CA14 | |
| SCHEMBL21164434 | 0.86 | PSIP1 (0.44) | CA2CA1CCR5 | |
| SCHEMBL20372757 | 0.86 | CCR5 (0.41) | CA2CA1CCR5 | |
| SCHEMBL21164503 | 0.83 | CCR5 (0.39) | CA2CA1CCR5 | |
| SCHEMBL21164370 | 0.82 | TNNI3K (0.41) | CA2CA1CCR5 | |
| SCHEMBL20372807 | 0.80 | NR1I2 (0.54) | CA2CA1CA12CA9CA14 | |
| SCHEMBL18509335 | 0.80 | HDAC4 (0.56) | CA2CA1CA12CA9CA14 | |
| SCHEMBL17367964 | 0.79 | DRD2 (0.42) | CA2CA1CCR5 | |
| SCHEMBL5262049 | 0.79 | CA2 (0.53) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CA2 3523/4885CA1 3748/4885CA12 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.